A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer

CONCLUSIONS: Oncolytic viral therapy with intraperitoneal Olvi-Vec showed promising safety, clinical activities, and immune activation in patients with PRROC, warranting further clinical investigation.PMID:34686353 | DOI:10.1016/j.ygyno.2021.10.069

Source: Gynecologic Oncology - October 23, 2021 Category: Cancer & Oncology Authors: Madhavi Manyam Amanda J Stephens Jessica A Kennard Jane LeBlanc Sarfraz Ahmad James E Kendrick Robert W Holloway Source Type: research